Table 2.
Baseline characteristics of patients with PES or non/unknown PES group.
| PES group | Non-PES or unknown group | P value | |
|---|---|---|---|
| N = 71 | N = 744 | ||
| Age (yr) Mean ± SD | 72.46 ± 14.02 | 75.23 ± 14.57 | .073 |
| Gender, Male, n (%) | 51 (71.8%) | 530 (71.2%) | .916 |
| Myocardial infarction, n (%) | 2 (2.8%) | 54 (7.3%) | .158 |
| Congestive heart failure, n (%) | 8 (11.3%) | 107 (14.4%) | .471 |
| Peripheral vascular disease, n (%) | 2 (2.8%) | 19 (2.6%) | .894 |
| CVA, n (%) | 5 (7.0%) | 77 (10.3%) | .376 |
| Dementia, n (%) | 12 (16.9%) | 134 (18.0%) | .816 |
| Chronic pulmonary disease, n (%) | 26 (36.6%) | 192 (25.8%) | .049* |
| Connective tissue disease, n (%) | 4 (5.6%) | 38 (5.1%) | .848 |
| Peptic ulcer disease, n (%) | 7 (9.9%) | 70 (9.4%) | .901 |
| Liver disease, n (%) | 3 (4.2%) | 50 (6.7%) | .415 |
| Diabetes mellitus, n (%) | 22 (31.0%) | 263 (35.3%) | .461 |
| Hemiplegia, n (%) | 10 (14.1%) | 101 (13.6%) | .905 |
| Moderate to severe CKD, n (%) | 9 (12.7%) | 124 (16.7%) | .385 |
| Solid tumor, n (%) | 7 (9.9%) | 69 (9.3%) | .871 |
| Leukemia, n (%) | 0 (0.0%) | 7 (0.9%) | .412 |
| Lymphoma, n (%) | 0 (0.0%) | 1 (0.1%) | .757 |
| AIDS, n (%) | 0 (0.0%) | 3 (0.4%) | .592 |
| Charlson score | 5.61 ± 2.70 | 5.95 ± 2.69 | .264 |
| APACHE II score | 20.63 ± 8.79 | 22.15 ± 7.05 | .250 |
| SOFA score | 6.24 ± 3.80 | 7.02 ± 3.75 | .344 |
| qSOFA score | 1.92 ± 0.51 | 1.74 ± 0.74 | .459 |
| Treatment duration (d) | 10.25 ± 4.84 | 9.11 ± 3.51 | .108 |
| Primary outcome, n (%) | .021* | ||
| Clinical cure | 51 (71.8%) | 614 (82.9%) | |
| Failure/Indeterminate | 20 (28.2%) | 127 (17.1%) | |
| Secondary outcome, n (%) | .200 | ||
| Effective | 56 (78.9%) | 630 (84.7%) | |
| Ineffective/Indeterminate | 15 (21.1%) | 114 (15.3%) | |
| In-hospital mortality, n (%) | 19 (26.8%) | 120 (16.1%) | .023* |
AIDS: = acquired immune deficiency syndrome, CKD = chronic kidney diseases, CVA = cerebral vascular accident, PES = Pseudomonas aeruginosa, extended-spectrum β-lactamase Enterobacteriaceae, and methicillin-resistant Staphylococcus aureus.
*
P < 0.05.